BioCentury
ARTICLE | Financial News

Karyopharm planning $115 million follow-on

March 25, 2014 12:17 AM UTC

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) proposed to raise up to $115 million in a follow-on underwritten by BofA Merrill Lynch; Leerink Partners; JMP Securities; Wedbush PacGrow; and Oppenheimer. Karyopharm's selinexor ( KPT-330) is in Phase II testing to treat relapsed glioblastoma multiforme (GBM) and ovarian, cervical and uterine carcinomas. The company plans to start registration-directed trials for acute myelogenous leukemia (AML) this half, for diffuse large B cell lymphoma (DLBCL) in late summer and for Richter's syndrome in mid-2014. This year, Karyopharm also expects to start Phase II testing in squamous head, neck or lung cancers and prostate cancer. ...